GICS Sector : Healthcare
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally.It offers dried cannabis inflorescences and cannabis extract mixed with oil.The company also invests in biomed sector.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
InterCure (NASDAQ:INCR) Shares Up 0.7% – Time to Buy?
Nov -22
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
Nov -03
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
Oct -08
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
Sep -19
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025
May -01
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
Feb -12
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
Dec -20
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
Sep -14
Growing demand for medical and recreational cannabis, increasing legalization, and InterCure's high-quality pharmaceutical-grade products position the company for significant growth in the global cannabis market.
High-quality cannabis flowers for medical and recreational use
Concentrated cannabis oil for medical and recreational use
Portable and discreet cannabis vaporizers for on-the-go use
Cannabis-infused food and beverages for recreational and medical use
Cannabis-infused creams, balms, and salves for localized relief
Cannabis-based pharmaceuticals for medical treatment
The threat of substitutes for InterCure Ltd. is medium due to the availability of alternative products in the market.
The bargaining power of customers for InterCure Ltd. is high due to the concentration of buyers in the market.
The bargaining power of suppliers for InterCure Ltd. is low due to the availability of multiple suppliers in the market.
The threat of new entrants for InterCure Ltd. is medium due to the moderate barriers to entry in the market.
The intensity of rivalry for InterCure Ltd. is high due to the high level of competition in the market.
| Value | |
|---|---|
| Debt Weight | 30.07% |
| Debt Cost | 5.15% |
| Equity Weight | 69.93% |
| Equity Cost | 5.15% |
| WACC | 5.15% |
| Leverage | 43.00% |
Value: 3.9
Growth: 6.6
Quality: 9.0
Yield: 2.5
Momentum: 4.0
Volatility: 7.0
1-Year Total Return ->
Value: 1.8
Growth: 6.6
Quality: 8.1
Yield: 3.1
Momentum: 0.5
Volatility: 5.0
1-Year Total Return ->
Value: 9.0
Growth: 2.3
Quality: 2.9
Yield: 0.0
Momentum: 3.5
Volatility: 1.0
1-Year Total Return ->
Value: 0.6
Growth: 3.0
Quality: 4.2
Yield: 0.0
Momentum: 8.5
Volatility: 1.3
1-Year Total Return ->
Value: 6.6
Growth: 2.3
Quality: 5.2
Yield: 0.0
Momentum: 0.0
Volatility: 2.3
1-Year Total Return ->
Value: 3.6
Growth: 4.0
Quality: 2.5
Yield: 0.0
Momentum: 2.5
Volatility: 1.0
1-Year Total Return ->